Latest Lead News

Cleanaway Waste Management Limited reported a robust first half of FY25 with double-digit EBIT growth and margin expansion, reinforcing confidence in meeting FY25 guidance and ambitious FY26 targets despite operational challenges.

Cleanaway Waste Management Limited has announced a fully franked ordinary dividend of AUD 0.028 per share, payable on April 10, 2025, with a Dividend Reinvestment Plan available for shareholders.

Iluka Resources Limited has announced a fully franked ordinary dividend of AUD 0.04 per share for the financial year ending December 31, 2024, with key dates set for March 2025.

EBOS Group Limited announces the retirement of CEO John Cullity after a decade of strong growth, appointing Adam Hall as his successor to lead the company’s next phase of expansion.

EBOS Group Limited posted a strong half-year performance with underlying EBITDA up 7.1% to $291 million, driven by growth in healthcare and animal care segments, while maintaining its interim dividend amid the loss of the Chemist Warehouse contract.

Meridian Energy has agreed to acquire NZ Windfarms for $91 million, aiming to streamline financing and boost capacity at the Te Rere Hau Wind Farm. The deal, supported by key shareholders, marks a significant step in New Zealand’s renewable energy landscape.

Mineral Resources Limited reported a challenging first half of 2025 with significant profit declines amid weaker commodity prices, yet delivered record earnings in Mining Services and advanced its transformative Onslow Iron project.

Adriatic Metals has completed a two-tranche institutional placement raising A$80 million to fast-track its Vares Processing Plant expansion and support production growth at Rupice Mine.

FFI Holdings Limited has announced a fully franked ordinary dividend of AUD 0.10 per share for the half-year ending December 2024, payable in April 2025. The company also offers shareholders a Dividend Reinvestment Plan with a 5% discount.

Atturra Limited reports a robust first half of FY25 with revenue growth nearing 28%, driven by recent acquisitions and expanding service offerings, while updating full-year guidance amid cautious government sector risks.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.